ASCO 2017 | What is the best treatment regimen for MM?
Laurent Garderet
• 1 Jun 2017
Laurent Garderet, MD, from Hopital Saint-Antoine, Paris, France, talks to us about the complexity of current treatments for multiple myeloma (MM) due to the availability of doublet and triplet drug combinations. He notes that generally for relapsed MM patients, a triplet regimen, usually RVD (revlimid-velcade-dexamethasone) is the gold-standard treatment, although a subset of patients may not benefit from this regimen. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.
